Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625000137493
Ethics application status
Approved
Date submitted
15/01/2025
Date registered
6/02/2025
Date last updated
19/06/2025
Date data sharing statement initially provided
6/02/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
Supplemental Tackifier to Intravenous Catheter dressings to Keep intact Year-round in Kids (the STICKY Kids trial).
Query!
Scientific title
Supplemental Tackifier to Intravenous Catheter dressings to Keep intact Year-round in Kids (the STICKY Kids trial).
Query!
Secondary ID [1]
312493
0
nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
STICKY Kids
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Central venous access device dressing complications
334350
0
Query!
Central venous access device related adverse events
334351
0
Query!
Condition category
Condition code
Public Health
332013
332013
0
0
Query!
Health service research
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Mastisol Liquid Adhesive (0.6ml individual vial blister pack) will be applied in conjunction with standard care dressing for central venous access devices (CVAD). This will occur each time the dressing is required to be changed based on clinical requirement due to altered dressing integrity, and at least once weekly as per organisational policy. This will continue at each dressing change for up to 8 weeks or until the CVAD is removed (whichever occurs first).
All dressing changes including application of the Mastisol Liquid Adhesive will be clinically managed by the Hospital in the Home (HITH) nursing team and will take place in the home care environment.
Data will be collected by the HITH nursing team on a paper-based data collection tool which will be returned to the research team daily. Additional data will be collected from the electronic medical record, and directly from the patient/ family where required.
Query!
Intervention code [1]
329742
0
Prevention
Query!
Comparator / control treatment
Children not randomised to the intervention arm will continue to receive standard care dressing for central venous access devices. Standard care dressing is defined as a bordered transparent polyurethane dressing, with the use of additional device securement devices as clinically indicated (including subcutaneously anchored securement systems and sutureless securement devices)
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
339616
0
Dressing Disruption during routine dressing schedule. Defined as the requirement for any CVAD dressing to be replaced prematurely and/or re-enforced due to disruption in dressing integrity at (e.g., lifted/detached on any border edge or within the transparent portion of dressing; visibly soiled; presence of moisture, drainage, or blood) prior to scheduled dressing change (before planned/routine change at seven days or catheter removal)
Query!
Assessment method [1]
339616
0
Daily visual assessment of the dressing, and documentation of dressing condition from the patient's medical records.
Query!
Timepoint [1]
339616
0
Daily from time of application of allocated dressing, for up to 8 weeks or until the CVAD is removed (whichever occurs first).
Query!
Secondary outcome [1]
440603
0
Cost (composite of cost and number of products used, cost of treating complications, staff time). Number of products used will be totalled from application of allocated dressing to CVC removal as per information gained via visual inspections of the dressings and patient medical records. Cost of products used will be based on standard hospital costs. Costs of treating complications will be determined using a micro-costing approach with detailed resource use recorded in terms of procedures/treatments to rectify dressing-related complications. Staff time will be calculated using local staffing wage rates (per hour), multiplied by time required to change dressings and number of dressing changes required.
Query!
Assessment method [1]
440603
0
Visual assessment, staff timings using purpose built data collection form and collection from medical record
Query!
Timepoint [1]
440603
0
At each dressing change until device removal or up to 8 weeks (whichever occurs first)
Query!
Secondary outcome [2]
440600
0
Primary bloodstream infection
Query!
Assessment method [2]
440600
0
Daily assessment of the CVAD, and documentation in the patient's medical records. Infectious outcomes will then be assessed by an infectious disease specialist (using Centers for Disease Control NHSN 2024 criteria) blinded to treatment allocation to confirm infectious outcome.
Query!
Timepoint [2]
440600
0
Daily until device removal or up to 8 weeks (whichever occurs first)
Query!
Secondary outcome [3]
444390
0
Blockage/ occlusion (partial/complete, with or without leakage)
Query!
Assessment method [3]
444390
0
Daily assessment of the CVAD by the HITH nursing team and review of documentation in the patient's medical records.
Query!
Timepoint [3]
444390
0
Daily until device removal or up to 8 weeks (whichever occurs first)
Query!
Secondary outcome [4]
444388
0
Local infection
Query!
Assessment method [4]
444388
0
Daily assessment of the CVAD, and review of documentation in the patient's medical records. Infectious outcomes will then be assessed by an infectious disease specialist blinded to treatment allocation to confirm infectious outcome.
Query!
Timepoint [4]
444388
0
Daily until device removal or up to 8 weeks (whichever occurs first)
Query!
Secondary outcome [5]
440599
0
Dressing dwell time in days (from application to intervention [requiring dressing change or re-enforcement] for each dressing change period) within the routine dressing schedule (7 days; up to week 8)
Query!
Assessment method [5]
440599
0
Daily visual assessment of the dressing, and documentation in the patient's medical records.
Query!
Timepoint [5]
440599
0
Daily from dressing application to intervention [requiring dressing change or re-enforcement] for each dressing change period - up to 8 weeks or until CVAD removal (whichever occurs first).
Query!
Secondary outcome [6]
440601
0
All cause CVAD failure (premature device removal due to pain, thrombosis, occlusion, infection and dislodgement)-during study period
Query!
Assessment method [6]
440601
0
Daily visual assessment of the CVAD, and documentation in the patient's medical records. Infection or thrombotic outcomes will then be assessed by an infectious disease specialist, and radiologist respectively blinded to treatment allocation to confirm infectious or thrombotic outcome.
Query!
Timepoint [6]
440601
0
Daily until device removal or up to 8 weeks (whichever occurs first)
Query!
Secondary outcome [7]
440598
0
Dressing Disruption Counts (defined as requirement for any intravenous catheter dressing to be replaced prematurely and/or re-enforced due to disruption in dressing integrity (e.g., Dressing disruption counts. Defined as requirement for any intravenous catheter dressing to be replaced prematurely and/or reinforced due to disruption in dressing integrity (e.g. lifted/detached on any border edge or within transparent portion of dressing; visibly soiled; presence of moisture, drainage, or blood) during study period
Query!
Assessment method [7]
440598
0
Daily visual assessment of the dressing, and documentation of dressing condition from the patient's medical records.
Query!
Timepoint [7]
440598
0
Daily until device removal or up to 8 weeks
Query!
Secondary outcome [8]
440602
0
Skin adverse event profiles (e.g., rash, blister, itchiness, skin tears, MARSI) during the study period
Query!
Assessment method [8]
440602
0
Visual assessment of skin at dressing site, and and documentation in the patient's medical records.
Query!
Timepoint [8]
440602
0
Daily until device removal or up to 8 weeks (whichever occurs first)
Query!
Secondary outcome [9]
444391
0
Dislodgement (complete or partial)
Query!
Assessment method [9]
444391
0
Daily assessment of the CVAD by the HITH nursing team and review of documentation in the patient's medical records.
Query!
Timepoint [9]
444391
0
Daily until device removal or up to 8 weeks (whichever occurs first)
Query!
Secondary outcome [10]
440604
0
Overall patient/parent satisfaction at dressing change (0 = not at all satisfied to 10 = completely satisfied).
Query!
Assessment method [10]
440604
0
Self-reported using 11-point Likert scale
Query!
Timepoint [10]
440604
0
At each dressing change from application of allocated dressing until device removal or 8 weeks (whichever occurs first)
Query!
Secondary outcome [11]
444389
0
Infiltration and extravasation (composite)
Query!
Assessment method [11]
444389
0
Daily assessment of the CVAD by the HITH nursing team and review of documentation in the patient's medical records. Infectious outcomes will then be assessed by an infectious disease specialist blinded to treatment allocation to confirm infectious outcome.
Query!
Timepoint [11]
444389
0
Daily until device removal or up to 8 weeks (whichever occurs first)
Query!
Secondary outcome [12]
440605
0
Overall clinician satisfaction with dressing regime at dressing application and removal (0 = not at all satisfied to 10 = completely satisfied
Query!
Assessment method [12]
440605
0
Self-reported using 11-point Likert scale
Query!
Timepoint [12]
440605
0
At each dressing change from application of allocated dressing until device removal or 8 weeks (whichever occurs first)
Query!
Eligibility
Key inclusion criteria
less than or equal to 18 years at recruitment
Patient expected to require central venous access device > 7 days
Requiring intravenous treatment in Hospital in the Home (HITH)
Informed consent to participate.
Vessel size appropriate for >3fr catheter or larger
Query!
Minimum age
0
Years
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Under the care of child services (if unable to obtain consent)
Patient receiving end-of-life care.
Allergy to study product
Significantly impaired skin surrounding insertion site of vascular access device (e.g., eczema, burn, open wound)
<3fr device
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Web based central randomisation service (REDCap)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Patients will be randomised to the MLA (and standard care) or standard care groups in a 1:1 ratio, with randomly varied block sizes of 4 and 6. Patients will be stratified by age (0 - 2 years, >2 – 12 years, >12 – 18 years), and timing of intervention (initial dressing or subsequent dressing)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Summaries of continuous variables that are normally distributed will be presented as means and standard deviations or as medians and inter-quartile ranges for skewed data. Categorical variables will be presented as frequencies and percentages.
All randomised patients will be analysed by intention-to-treat as primary analysis. A per-protocol analysis will assess the effect of protocol violations. The primary outcome, dressing disruption, will be analysed using mixed effects logistic regression with ‘treatment’ as the main effect and child as a random effect to account for repeated observations. Kaplan-Meier survival curves (with log-rank Mantel-Cox test) will compare dressing disruption over time. All tests will be two-sided, with a significance level set at 0.05.
Other secondary clinical outcomes will be compared between groups with appropriate parametric or non-parametric techniques. For outcomes collected weekly, mixed effects models will be used. For outcomes collected over the entire study period, logistic regression (for binary outcomes) or Poisson regression (for count data) will be used.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/04/2025
Query!
Actual
17/06/2025
Query!
Date of last participant enrolment
Anticipated
31/12/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
31/03/2027
Query!
Actual
Query!
Sample size
Target
104
Query!
Accrual to date
1
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
26772
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment postcode(s) [1]
42823
0
4101 - South Brisbane
Query!
Funding & Sponsors
Funding source category [1]
316913
0
Commercial sector/Industry
Query!
Name [1]
316913
0
Eloquest Healthcare, Inc
Query!
Address [1]
316913
0
Query!
Country [1]
316913
0
United States of America
Query!
Primary sponsor type
University
Query!
Name
University of Queensland
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
320503
0
None
Query!
Name [1]
320503
0
Query!
Address [1]
320503
0
Query!
Country [1]
320503
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
315671
0
Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee
Query!
Ethics committee address [1]
315671
0
http://www.childrens.health.qld.gov.au/research/human-research-ethics-committee
Query!
Ethics committee country [1]
315671
0
Australia
Query!
Date submitted for ethics approval [1]
315671
0
02/12/2024
Query!
Approval date [1]
315671
0
16/01/2025
Query!
Ethics approval number [1]
315671
0
Query!
Summary
Brief summary
The objective of this study is to determine if the use of Mastisol Liquid Adhesive in conjunction with standard care reduces dressing disruption prior to scheduled weekly dressing change and is associated with fewer CVAD complications in children receiving in-home care.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
135450
0
Ms Tricia Kleidon
Query!
Address
135450
0
Queensland Children's Hospital, 501 Stanley Street South, Brisbane, QLD 4101
Query!
Country
135450
0
Australia
Query!
Phone
135450
0
+61 07 3068 5160
Query!
Fax
135450
0
Query!
Email
135450
0
[email protected]
Query!
Contact person for public queries
Name
135451
0
Tricia Kleidon
Query!
Address
135451
0
Queensland Children's Hospital, 501 Stanley Street South, Brisbane, QLD 4101
Query!
Country
135451
0
Australia
Query!
Phone
135451
0
+61 07 3068 5160
Query!
Fax
135451
0
Query!
Email
135451
0
[email protected]
Query!
Contact person for scientific queries
Name
135452
0
Tricia Kleidon
Query!
Address
135452
0
Queensland Children's Hospital, 501 Stanley Street South, Brisbane, QLD 4101
Query!
Country
135452
0
Australia
Query!
Phone
135452
0
+61 07 3068 5160
Query!
Fax
135452
0
Query!
Email
135452
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF